Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
20 Novembro 2023 - 6:05PM
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology
company seeking to develop medicines for broad populations of
cancer patients with an initial aim to develop a universal-RAS
therapy, today announced that management will present at the
35th Annual Piper Sandler Healthcare Conference to discuss the
company’s pipeline, platform, and business strategy. Participating
will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer,
Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.”
Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief
Accounting Officer, Treasurer.
Format: Fireside chat and 1x1 Investor
MeetingsPresentation: November 30, 2023 from 11:30 – 11:55 am
ET
The presentations will be webcast live and
archived in the Investor Relations section of Immuneering’s website
at Events & Presentations | Immuneering Corporation.
About Immuneering
Corporation
Immuneering is a clinical-stage oncology company seeking to
develop medicines for broad populations of cancer patients with an
initial aim to develop a universal-RAS therapy. The Company aims to
achieve universal activity through deep cyclic inhibition of the
MAPK pathway, impacting cancer cells while sparing healthy cells.
Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a
study in patients with advanced solid tumors harboring RAS
mutations. The company’s development pipeline also includes
IMM-6-415, a universal-MAPK program, as well as several early-stage
programs. For more information, please visit
www.immuneering.com.
Media Contact:Gina Nugent Nugent
Communications 617-460-3579 gina@nugentcommunications.com
Investor Contacts: Laurence
Watts Gilmartin
Group 619-916-7620 laurence@gilmartinir.com
or
Kiki Patel, PharmD Gilmartin
Group 332-895-3225kiki@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immuneering (NASDAQ:IMRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024